Latest Europe News

Gowing Bros’ FY2026 loss widened to $3.49 million as Surf Hardware International remained deeply loss-making and investment properties were marked down by $3.0 million. The ASX-listed investment company kept its fully franked final dividend at 3 cents per share, despite negative operating cash flow and lower cash reserves.

Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.

AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.

EQ Resources has completed a sharp financial turnaround, moving from solvency concerns to a A$7.1 million FY2026 profit and A$28.2 million of cash. The recovery comes with lower annual production, serious safety shortcomings and substantial dilution, leaving execution as the test for its A$39 million Mt Carbine expansion.

Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.

Brazilian Critical Minerals has reported striking economics for its Ema rare earths project, including a US$1.47 billion post-tax NPV, 105% IRR and six-month payback. The company’s A$7.87 million FY2026 loss, December debt maturity, permitting requirements and unresolved Drake dispute leave the development case dependent on execution and further funding.

Delegat Group delivered record operating earnings and cash flow in FY26, but reported profit fell after a NZ$8.7 million impairment and other fair-value adjustments. The NZX-listed wine company is forecasting higher case sales and operating NPAT of NZ$62 million to NZ$66 million for FY27.

AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.

Nico Resources is advancing drilling, metallurgical studies and a potential downstream battery-materials partnership at Wingellina, despite a subdued nickel market and a larger annual loss. The company ended FY2026 with $4.73 million across cash and short-term investments after raising $3.73 million in equity.

Victory Metals has set out a 20-year development case for North Stanmore, backed by a 47 million tonne Probable Ore Reserve and a pre-tax NPV8 of A$1.76 billion. The project remains pre-feasibility stage, while the company ended FY2026 with A$11.18 million in cash and no operating revenue.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.